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Xp11 translocation renal cell carcinoma (TRCC) is a rare subtype of renal cell carcinoma characterized by
chromosomal translocations involving the TFE3 gene located at the Xp11.2 locus. Initial cases were more
common in children, but cases in older adults have begun to accrue and suggest a relatively more
aggressive course. We report a case of Xp11 TRCC in a 63-year-old female patient with initial presen-
tation mimicking upper urinary tract urothelial cell carcinoma, with biopsy proving TRCC. She under-
went a radical nephrectomy and paracaval lymph node dissection and is followed up with the intent to
initiate vascular endothelial growth factoretargeted therapy in case of recurrence.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Initially thought to be a malignancy affecting the pediatric and
young adult population, recent studies have identiﬁed Xp11
translocation renal cell carcinoma (TRCC) in older adults. Incidence
ranges from 0.95% to 5% of all adult renal cell carcinomas (RCCs).1
Considering that RCC is more prevalent in adults than children,
Xp11 TRCC in adults represents a greater number of tumors as a
whole than Xp11 TRCC in children. Compared with its more
indolent presentation in the pediatric population, older adults
usually present with advanced stage and distant metastasis.2
Prognosis is generally poor, and adult patients often succumb to
a rapid terminal course despite aggressive surgical intervention.3
Although the most favorable outcomes have been reported with
patients who undergo a radical nephrectomy and lymph node
dissection before the development of metastasis, successful and
reliable treatment regimens are lacking.4 For the patients who
undergo radical nephrectomy, the challenge then lies in follow-up.
A unique surveillance protocol has yet to be developed, although
many agree that these patients should be categorized as high
risk.2,3 Clinicians should be aware of this rare variant and various
presentations to ensure appropriate patient management and
surveillance.BY-NC-ND license (http://
: þ1-352-273-7515.
. Akhavein).
Published by Elsevier Inc. All righCase presentation
A 63-year-old womanwas referred to us for a right renal pelvic
mass detected on ultrasound during a gross hematuria and ﬂank
pain evaluation. Urine cytology was negative for malignancy, and
computed tomography (CT) showed high-grade obstruction of
the right kidney secondary to a 3.5-cm inﬁltrative lesion
involving the proximal collecting systemwith inﬁltration into the
superior renal pole parenchyma. The patient also had diffuse
retroperitoneal and pelvic lymphadenopathy and splenomegaly,
which were attributed to her chronic lymphocytic leukemia (CLL)
currently in remission on the basis of comparison with previous
imaging. In addition to CLL, past medical history included
Moyamoya disease, transient ischemic attacks, hypertension,
diabetes mellitus type 2, ﬁbromyalgia, seizure disorder, asthma,
and hypothyroidism due to thyroidectomy for papillary thyroid
cancer. She remained highly functional despite her medical
comorbidities. Chest CT revealed no evidence of metastasis, and
the patient was counseled on the need for ureteroscopic biopsy
for tissue diagnosis.
Cystoscopy showed no abnormal ﬁndings. Retrograde ureter-
opyelogram identiﬁed a large ﬁlling defect within the right renal
pelvis extending all theway to themid ureter. Flexible ureteroscopy
revealed a large, elongated, and pale ﬂeshy-appearingmass that did
not appear to be consistent with urothelial carcinoma, but rather
resembling a necrotic ﬁbroepithelial polyp. The non-necrotic parts
of tumor were biopsied despite extensive clot surrounding this
mass which made visualization extremely challenging. Two largets reserved.
Figure 1. Composite photomicrograph showing the characteristic features of Xp11 translocation renal cell carcinoma. (A) Low power view (40) showing an exophytic tumor
(double arrows) in the renal pelvis (arrow). The tumor has a papillary growth pattern (B; 40) and is composed of voluminous cells (C, 200) with clear and eosinophilic cytoplasm.
Note the delicate blood vessels inside the papillae. Immunohistochemistry for TEF3 shows nuclear immunoreactivity (200).
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histochemical studies showed that the tumor cells were partially
PAX8(þ), CD10(þ), CK7(), p63(), GATA3(), and MiTF() with
strong immunoreactivity for TFE3, excluding urothelial carcinoma.
Considering the aggressive nature of Xp11 TRCC, the decision was
made with the patient and family to promptly undergo a rightTable 1
Case reports in the literature of Xp11 TRCC in patients older than 55 years
Author Demographics Presentation
Haudebourg et al5 57-y-old female
patient
4.5-cm solid right, inferior pole renal ma
calciﬁcations seen on CT. Biopsy showed
and alveolar growth pattern composed
cells, consistent with clear cell RCC.
Salles et al6 58-y-old female
patient
4.8-cm mass in middle, third of right kid
MRI. Presented with infrequent nephrit
for 6mo, no ﬁndings on physical examin
urine sediment and culture.
LaGrange et al7 63-y-old female
patient
3-cm right renal mass seen incidentally
during evaluation for left lower quadran
abdominal pain.
Franzini et al8 79-y-old male
patient
Presented with gross intermittent hema
Sonography showed spherical left kidne
increased total size, without evidence o
cortiocomedullary differentiation becau
parenchymal dyshomogeneity with neo
aspect, conﬁrmed by CT, which also sho
gross nodal involvement. Angiography s
massive thrombotic involvement of ren
CT, computed tomography; MRI, magnetic resonance imaging; RCC, renal cell carcinomalaparoscopic radical nephrectomy and regional lymphadenectomy,
which were performed without complications.
Surgical pathology revealed pT3aN1Mx, Xp11.2-associated clear
cell RCC, with Fuhrman nuclear grade 4 and negative margins
(Fig. 1). One of 4 lymph nodes was positive for metastatic carci-
noma, and the lymph nodes were effaced by a diffuse lymphocyticTreatment Outcome
ss with
solid
of clear
Emergency nephrectomy because of
retroperitoneal hemorrhage,
pT1bNxMx, grade 3.
Immunohistochemistry and FISH
positive for TFE3, cytogenetic analysis
showed t(X;1)(p11.2;p34). Additional
karyotypic alterations were monosomy
18, monosomy 21, and trisomy 20.
No evidence of disease at
follow-up period of 13 mo
ney on
ic colic
ation or
Radical nephrectomy, pT1bN2MX,
Immunochemistry positive for TFE3.
No evidence of disease at 6
mo of follow-up.
on CT
t
Hand-assisted laparoscopic partial
nephrectomy, pT1aNxMx.
Immunohistochemistry positive for
TFE3 and vimentin, negative for
cytokeratin and epithelial membrane
antigens.
No evidence of disease at 24
mo of follow-up.
turia.
y with
f
se of
plasm
wed
howed
al vein.
Radical nephrectomy with
thrombectomy and staging
lymphadenectomy. Pathology showed
kidney parenchyma substituted by
white ﬁrm tissue and multiple node
metastases. Immunhistochemistry
positive for TFE3 and CD10 and negative
for cytokeratin and epithelial
membrane antigens.
Postoperative time
uneventful except for
lymphorrhea, discharged
on postoperative day 14.
One month later develops
massive thrombosis of the
portal vein and dies.
.
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the aggressive course of Xp11 TRCC, she was referred to the
medical oncology service for consideration of adjuvant chemo-
therapy or targeted therapy. Because of the lack of evidence for
any beneﬁt with these treatment modalities on this unique
pathologic entity and no other foci of disease found on the pa-
tient’s postoperative positron emission tomography-CT, adjuvant
therapy was deferred to the time of possible future recurrence.
Discussion
Data regarding older adults are limited, and a review of the
literature identiﬁed only 4 reports discussing Xp11 TRCC in patients
older than 55 years, 5e8 as summarized in Table 1. However, the
incidence of this rare neoplasm may be underestimated with the
true frequency unknown in patients older than 40 years because of
its histologic features that oftenmimic clear cell and papillary RCC.9
Misdiagnoses may be further compounded by the fact that TFE3
immunohistochemistry and cytogenetic studies are not routinely
done and there is signiﬁcant histologic overlap with TFE3 negative
and TFE3 positive RCC. Our case illustrates the importance of per-
forming immunohistochemical analyses in suspicious cases, as the
distinction of Xp11 TRCC is crucial in providing appropriate coun-
seling and determining surveillance protocol and management.
Cytogenetic analyses are another helpful modality to diagnose Xp11
TRCC and should be used alongside immunohistochemistry.
Despite the literature suggesting the propensity of adult Xp11
TRCC to progress rapidly, 3 reports in adults older than 55 yearswith
ﬁnal pathologic stages pT1aN0Mx, pT1bN0Mx, and pT1bN2Mx
disease found no evidence of disease at 24, 13, and 6 months,
respectively.5e7 The fourth case involved the oldest patient of 79
years with pT3a disease andmultiple positive lymph nodes without
distant metastasis.8 The patient underwent a radical nephrectomy
without adjuvant chemotherapy but passed away approximately 44
days after the operation frommassive thrombosis of the portal vein.
Our case presents an elderly patient with advanced T3aN1Mx dis-
ease, more consistent with the existing literature that suggests a
relatively aggressive clinical course in adults. The patient was
referred to medical oncology for evaluation of adjuvant chemo-
therapy, as there are emergingdata suggestingefﬁcacyof agents that
target vascular endothelial growth factor and mammalian target of
rapamycin pathways.10 These agents have been shown to havemodest effects in the setting of metastatic disease and appear to be
the optimal agents for management of metastatic Xp11 TRCC.
Conclusion
Considering the rising incidence of RCC with the increased use
of cross-sectional imaging, clinicians should be aware of Xp11
TRCC as a unique tumor and its propensity for rapid progression in
adults to facilitate appropriate patient management. Considering
histologic overlap of Xp11 TRCC with other RCC subtypes, it is
imperative to perform immunohistochemistry and cytogenetics to
prevent misdiagnoses in borderline or suspicious cases. There is no
successful and reliable treatment regimen for Xp11 TRCC; how-
ever, the most favorable outcomes have been associated with
curative surgical excision with radical nephrectomy and lymph
node dissection. Literature in the older adult population is limited,
and outcomes data are still premature, making long-term follow-
up data necessary.
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